PPD, angling to stand out among CROs running pediatric trials, has cemented a network of 8 global sites to accelerate the process of starting studies on kids.
Switzerland-based Actelion is jumping into the vaccines industry by creating Vaxxilon, a startup that will focus on synthetic carbohydrate vaccines. It has licensed exclusive rights to multiple preclinical vaccines and other technologies from the Max Planck Society and will invest up to €30 million ($33 million), which will come in tranches over three to four years.
CRO BioClinica has opened new outposts in the U.K. and Germany, expanding its European footprint and scaling up its capabilities in medical imaging.
More than a year after announcing plans to spin out its drug business, Baxter has begotten Baxalta, a $6 billion standalone company with plans to elbow its way into the upper ranks of biopharma.
Royal Philips and Teva Pharmaceutical Industries are getting the ball rolling on their new med tech incubator in Israel, sinking funds into two startups and planning more investments in the months ahead.
Xenon Pharmaceuticals' Teva-partnered treatment for osteoarthritis pain missed its goals in a Phase IIb trial, a failure the biotech believes won't derail the drug's development in other indications.
Illumina is laying out plans for expansion, signing a 20-year lease on a 155,000-square-foot facility in Cambridge, England.
Ethicon, the Johnson & Johnson unit devoted to surgical tools, is moving to defend its bariatric surgery territory as a slew of noninvasive medical devices to treat obesity line up to gain approval in the U.S. It will spend $3.2 million on more than 20 clinical trials to examine how early surgical intervention can be used to improve conditions such as obesity and Type 2 diabetes.
Cynapsus kicked off patient enrollment in its Phase III clinical trial of sublingual apomorphine for Parkinson's patients who stop responding to levodopa.
French biotech Transgene is planning to slash its payroll and redouble its focus on clinical development, moving on from a costly snub at the hands of Novartis.